GER-009-06-AVX Early Therapy in Multiple Sclerosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00492570

Acronym

FIT

Enrollment

230

Registered

2007-06-27

Start date

2006-04-30

Completion date

2008-12-31

Last updated

2009-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing-Remitting Multiple Sclerosis

Keywords

Multiple Sclerosis, Cognitive Dysfunction in Multiple sclerosis, early treatment, Avonex, interferon beta 1a, Cognitive Dysfunction

Brief summary

This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.

Detailed description

This study will address the cognitive dysfunction associated with MS. It will track these changes and show that early intervention with Avonex is effective in slowing MS and its effect on patients. Safety data will also be collected during this study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* CIS (according to indication) or early Relapsing Remitting Multiple Sclerosis

Exclusion criteria

* treatment with DMT during the last 12 months

Outcome results